ESR1 and breast carcinoma: This last goal is clinically relevant because the commonly used chemo-therapies (tamoxifen, fulvestran, anti-estrogen analogues, aromatase inhibitors) against ER+ breast cancer do not always provide positive outcomes and such therapies are frequently associated with the development of severe side effects (15–17).